ArticleScientific reports2020

Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy.

Satoshi Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.